Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …

Triple-negative breast cancer (TNBC), defined as breast cancer lacking expression of
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 …

Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited
treatment options, namely chemotherapy. Different molecular studies have recently …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) and
accounts for 10–20% of cases. Due to the lack of expression of several receptors, hormone …

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative
breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options …

Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to
affect younger women, metastasise early despite optimal adjuvant treatment and carry a …

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its
extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic …

Opinion statement Triple-negative breast cancer (TNBC) accounts for 15% of all breast
cancers and is associated with poor long-term outcomes compared to other breast cancer …

Triple-negative breast cancer (TNBC) is associated with an increased risk of early
recurrence and distant metastasis, as well as the development of therapeutic resistance and …

Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer (BC)
with vicious behaviors. TNBC is usually associated with relatively poor clinical outcomes …